Total trials
1,268
Active
313
Phase 3
64
Total enrollment
1,414,479
Pipeline matrix
Showing 40 of 89 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin 10 MG | — | — | — | — | 3 | ||
| Dabigatran etexilate | — | — | — | — | 2 | ||
| Dulaglutide 0.75mg subcutaneous | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 | |
| Ketorolac 15mg | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide 40mg | — | — | — | — | — | 1 | |
| Ropivacaine HCL 1% 15ml | — | — | — | — | — | 1 | |
| 0.9 % Normal Saline 35ml | — | — | — | — | — | 1 | |
| Adrenaline 1:1000 0.5ml | — | — | — | — | — | 1 | |
| Live attenuated influenza vaccine | — | — | — | — | — | 1 | |
| recombinant hemagglutinin influenza vaccine | — | — | — | — | — | 1 | |
| Warfarin | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | — | 1 | |
| Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy | — | — | — | — | — | 1 | |
| Ivabradine + Usual Care | — | — | — | — | — | 1 | |
| Liposomal bupivacaine | — | — | — | 4 | |||
| Inactivated influenza vaccine | — | — | — | — | 2 | ||
| Dydrogesterone | — | — | — | — | — | 3 | |
| Berberine | — | — | — | — | — | 3 | |
| Yulinzhu | — | — | — | — | — | 1 | |
| 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion | — | — | — | — | — | 1 | |
| 0.1% Cyclosporin A cationic ophthalmic emulsion | — | — | — | — | — | 1 | |
| Prednisolone 30 mg | — | — | — | — | — | 1 | |
| IVF: Decapeptyl and hCG | — | — | — | — | — | 1 | |
| FET: Decapeptyl | — | — | — | — | — | 1 | |
| IVF: hCG and normal saline | — | — | — | — | — | 1 | |
| FET: Normal Saline | — | — | — | — | — | 1 | |
| Levonorgestrel | — | — | — | — | — | 1 | |
| Piroxicam | — | — | — | — | — | 1 | |
| LingZhi | — | — | — | — | — | 1 | |
| 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine | — | — | — | — | — | 1 | |
| 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone | — | — | — | — | — | 1 | |
| 0.5% standard bupivacaine only | — | — | — | — | — | 1 | |
| 1.33% liposomal bupivacaine with 0.5% standard bupivacaine | — | — | — | — | — | 1 | |
| 1.33% liposomal bupivacaine only | — | — | — | — | — | 1 | |
| semaglutide | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Ulipristal acetate | — | — | — | — | 2 | ||
| Silver diamine fluoride gel | — | — | — | — | — | 2 | |
| Carboplatin plus Paclitaxel | — | — | — | — | — | 2 |
49 more active programs hidden
Next readouts
- 2024-05-08
- 2024-09-01
- 2024-12-01
- 2025-07-01
- 2025-08-31
- 2025-09
- 2025-12
- 2025-12-30
- 2025-12-31
- 2025-12-31
Top conditions
- Smoking Cessation59
- Insomnia32
- Depressive Symptoms19
- Cancer18
- Smoking18
- Hypertension17
- Depression17
- Obstructive Sleep Apnea15
Frequently asked questions about The University of Hong Kong
- How many clinical trials does The University of Hong Kong have on ClinicalTrials.gov?
- The University of Hong Kong is listed as the lead sponsor on 1,268 clinical trials in ClinicalTrials.gov, 313 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The University of Hong Kong's trials are in Phase 3?
- 64 of The University of Hong Kong's trials are in Phase 3, spread across 89 active drug programs.
- What therapeutic areas does The University of Hong Kong focus on?
- The University of Hong Kong's most-studied conditions on ClinicalTrials.gov are Smoking Cessation, Insomnia, Depressive Symptoms, Cancer, Smoking.
- When are The University of Hong Kong's next clinical trial readouts?
- The University of Hong Kong has 10 upcoming primary-completion readouts tracked here; the soonest is “Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)”, expected around 2024-05-08.